Overall PHR gets a fundamental rating of 4 out of 10. We evaluated PHR against 35 industry peers in the Health Care Technology industry. While PHR seems to be doing ok healthwise, there are quite some concerns on its profitability. PHR is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year PHR has reported negative net income.
PHR had a positive operating cash flow in the past year.
In the past 5 years PHR always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PHR reported negative operating cash flow in multiple years.

1.2 Ratios

PHR has a better Return On Assets (-1.27%) than 71.43% of its industry peers.
PHR has a Return On Equity of -1.68%. This is in the better half of the industry: PHR outperforms 71.43% of its industry peers.

		Industry Rank	Sector Rank
ROA	-1.27%
ROE	-1.68%
ROIC	N/A

ROA(3y)-33.2%

ROA(5y)-26.37%

ROE(3y)-45.91%

ROE(5y)-35.28%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 68.20%, PHR is doing good in the industry, outperforming 68.57% of the companies in the same industry.
PHR's Gross Margin has been stable in the last couple of years.
PHR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	68.2%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.16%

GM growth 5Y1.12%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHR has more shares outstanding
PHR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHR has a worse debt to assets ratio.

2.2 Solvency

PHR has an Altman-Z score of 3.24. This indicates that PHR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PHR (3.24) is better than 74.29% of its industry peers.
PHR has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.27, PHR is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that PHR is not too dependend on debt financing.
The Debt to Equity ratio of PHR (0.01) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.27
Altman-Z	3.24

ROIC/WACCN/A

WACC9.67%

2.3 Liquidity

PHR has a Current Ratio of 2.44. This indicates that PHR is financially healthy and has no problem in meeting its short term obligations.
PHR has a Current ratio of 2.44. This is comparable to the rest of the industry: PHR outperforms 54.29% of its industry peers.
A Quick Ratio of 2.44 indicates that PHR has no problem at all paying its short term obligations.
PHR has a Quick ratio (2.44) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.44
Quick Ratio	2.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.75% over the past year.
PHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.33%.
The Revenue has been growing by 27.46% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)93.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%140%

Revenue 1Y (TTM)14.33%

Revenue growth 3Y25.34%

Revenue growth 5Y27.46%

Sales Q2Q%12.67%

3.2 Future

Based on estimates for the next years, PHR will show a very strong growth in Earnings Per Share. The EPS will grow by 44.72% on average per year.
The Revenue is expected to grow by 11.34% on average over the next years. This is quite good.

EPS Next Y119.12%

EPS Next 2Y62.07%

EPS Next 3Y44.72%

EPS Next 5YN/A

Revenue Next Year14.63%

Revenue Next 2Y14.86%

Revenue Next 3Y12.9%

Revenue Next 5Y11.34%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PHR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 20.07, the valuation of PHR can be described as rather expensive.
PHR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PHR is cheaper than 74.29% of the companies in the same industry.
PHR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	20.07

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHR is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, PHR is valued a bit cheaper than the industry average as 68.57% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	21.9
EV/EBITDA	33.57

4.3 Compensation for Growth

PHR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHR's earnings are expected to grow with 44.72% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y62.07%

EPS Next 3Y44.72%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PHR!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

PHREESIA INC

NYSE:PHR (2/4/2026, 8:04:00 PM)

After market: 12.83 0 (0%)

12.83

+0.05 (+0.39%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)12-08 2025-12-08/amc

Earnings (Next)03-10 2026-03-10/amc

Inst Owners102.75%

Inst Owner Change-0.87%

Ins Owners5.31%

Ins Owner Change4.94%

Market Cap768.65M

Revenue(TTM)463.20M

Net Income(TTM)-5.38M

Analysts84.55

Price Target29.74 (131.8%)

Short Float %5.41%

Short Ratio2.19

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)8258.63%

Min EPS beat(2)115.6%

Max EPS beat(2)16401.7%

EPS beat(4)4

Avg EPS beat(4)4149.43%

Min EPS beat(4)38.81%

Max EPS beat(4)16401.7%

EPS beat(8)8

Avg EPS beat(8)2083.66%

EPS beat(12)12

Avg EPS beat(12)1396.19%

EPS beat(16)16

Avg EPS beat(16)1052.44%

Revenue beat(2)0

Avg Revenue beat(2)-0.56%

Min Revenue beat(2)-0.76%

Max Revenue beat(2)-0.37%

Revenue beat(4)0

Avg Revenue beat(4)-0.4%

Min Revenue beat(4)-0.76%

Max Revenue beat(4)-0.18%

Revenue beat(8)1

Avg Revenue beat(8)-0.37%

Revenue beat(12)4

Avg Revenue beat(12)0.17%

Revenue beat(16)8

Avg Revenue beat(16)0.55%

PT rev (1m)-2.23%

PT rev (3m)-14.06%

EPS NQ rev (1m)53.42%

EPS NQ rev (3m)310.52%

EPS NY rev (1m)14.66%

EPS NY rev (3m)643%

Revenue NQ rev (1m)0.56%

Revenue NQ rev (3m)1.77%

Revenue NY rev (1m)0.14%

Revenue NY rev (3m)0.51%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	20.07
P/S	1.66
P/FCF	21.9
P/OCF	12.52
P/B	2.4
P/tB	4.66
EV/EBITDA	33.57

EPS(TTM)-0.07

EYN/A

EPS(NY)0.64

Fwd EY4.98%

FCF(TTM)0.59

FCFY4.57%

OCF(TTM)1.02

OCFY7.99%

SpS7.73

BVpS5.35

TBVpS2.75

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.27%
ROE	-1.68%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	68.2%
FCFM	7.58%

ROA(3y)-33.2%

ROA(5y)-26.37%

ROE(3y)-45.91%

ROE(5y)-35.28%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.16%

GM growth 5Y1.12%

F-Score7

Asset Turnover1.09

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.27
Debt/EBITDA	0.17
Cap/Depr	92.06%
Cap/Sales	5.68%
Interest Coverage	N/A
Cash Conversion	308.26%
Profit Quality	N/A
Current Ratio	2.44
Quick Ratio	2.44
Altman-Z	3.24

F-Score7

WACC9.67%

ROIC/WACCN/A

Cap/Depr(3y)91.68%

Cap/Depr(5y)107.3%

Cap/Sales(3y)7.37%

Cap/Sales(5y)9.81%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)93.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%140%

EPS Next Y119.12%

EPS Next 2Y62.07%

EPS Next 3Y44.72%

EPS Next 5YN/A

Revenue 1Y (TTM)14.33%

Revenue growth 3Y25.34%

Revenue growth 5Y27.46%

Sales Q2Q%12.67%

Revenue Next Year14.63%

Revenue Next 2Y14.86%

Revenue Next 3Y12.9%

Revenue Next 5Y11.34%

EBIT growth 1Y89.17%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year266.33%

EBIT Next 3Y65.66%

EBIT Next 5Y38.03%

FCF growth 1Y150.83%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y235.86%

OCF growth 3YN/A

OCF growth 5Y108.09%

PHREESIA INC / PHR FAQ

Can you provide the ChartMill fundamental rating for PHREESIA INC?

ChartMill assigns a fundamental rating of 4 / 10 to PHR.

What is the valuation status of PHREESIA INC (PHR) stock?

ChartMill assigns a valuation rating of 4 / 10 to PHREESIA INC (PHR). This can be considered as Fairly Valued.

Can you provide the profitability details for PHREESIA INC?

PHREESIA INC (PHR) has a profitability rating of 2 / 10.

What is the expected EPS growth for PHREESIA INC (PHR) stock?

The Earnings per Share (EPS) of PHREESIA INC (PHR) is expected to grow by 119.12% in the next year.

Can you provide the dividend sustainability for PHR stock?

The dividend rating of PHREESIA INC (PHR) is 0 / 10 and the dividend payout ratio is 0%.